Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Abbott Laboratories    ABT

ABBOTT LABORATORIES

(ABT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Abbott Laboratories : Gets Emergency Authorization for Serology Test

10/12/2020 | 09:28am EST

By Matt Grossman

Abbott Laboratories has received an emergency-use authorization from the Food and Drug Administration for a test to detect antibodies for the new coronavirus, the company said Monday.

The lab-based test detects IgM antibodies, using Abbott's Architect and Alinity platforms. Antibody tests can be used to determine if someone has had a recent or prior infection with SARS-CoV-2, the virus that causes Covid-19.

Abbott said that the test will compliment the company's already-developed test for IgG antibodies. IgG testing is better suited to determining whether someone has been infected in the longer term, while IgM testing is most useful for detecting whether someone has had a recent infection, Abbott said.

Write to Matt Grossman at matt.grossman@wsj.com

(END) Dow Jones Newswires

10-12-20 0927ET

All news about ABBOTT LABORATORIES
12/02ABBOTT LABORATORIES : FreeStyle Libre 2 Now Approved for Adults and Children wit..
AQ
11/20ABBOTT LABORATORIES : Change in Directors or Principal Officers (form 8-K)
AQ
11/19ABBOTT LABORATORIES : Becomes first anchor sponsor of american diabetes associat..
AQ
11/18ABBOTT LABORATORIES : Launches the first infant formula in canada with an ingred..
AQ
11/17ABBOTT LABORATORIES : Launches the First Infant Formula in Canada with an Ingred..
AQ
11/17ABBOTT LABORATORIES : Named industry sustainability leader for the eighth year i..
AQ
11/16HHS Official Says The Agency Has Responded To Every State That Has Requested ..
RE
11/16ABBOTT : Named Industry Sustainability Leader for the Eighth Year in a Row on th..
PR
11/12ABBOTT LABORATORIES : Entry into a Material Definitive Agreement, Termination of..
AQ
11/12ABBVIE : Vice Chairman, Chief Commercial Officer Carlos Alban to Retire
DJ
More news
Financials (USD)
Sales 2020 33 873 M - -
Net income 2020 4 415 M - -
Net Debt 2020 11 794 M - -
P/E ratio 2020 44,1x
Yield 2020 1,33%
Capitalization 192 B 192 B -
EV / Sales 2020 6,01x
EV / Sales 2021 5,23x
Nbr of Employees 107 000
Free-Float 88,9%
Chart ABBOTT LABORATORIES
Duration : Period :
Abbott Laboratories Technical Analysis Chart | ABT | US0028241000 | MarketScreener
Technical analysis trends ABBOTT LABORATORIES
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 118,44 $
Last Close Price 108,15 $
Spread / Highest target 20,2%
Spread / Average Target 9,52%
Spread / Lowest Target -24,2%
EPS Revisions
Managers
NameTitle
Robert B. Ford President, CEO, Chief Operating Officer & Director
Miles D. White Executive Chairman
Robert E. Funck Chief Financial Officer & Executive Vice President
Roxanne Schuh Austin Independent Director
Samuel C. Scott Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ABBOTT LABORATORIES24.51%191 681
MEDTRONIC PLC0.13%152 346
BECTON, DICKINSON AND COMPANY-11.07%70 150
HOYA CORPORATION24.59%48 552
ALIGN TECHNOLOGY, INC.81.15%39 857
BAXTER INTERNATIONAL INC.-8.69%39 001